304 related articles for article (PubMed ID: 33020573)
1. Berberine affects mitochondrial activity and cell growth of leukemic cells from chronic lymphocytic leukemia patients.
Ravera S; Ghiotto F; Tenca C; Gugiatti E; Santamaria S; Ledda B; Ibatici A; Cutrona G; Mazzarello AN; Bagnara D; Cardillo M; Zarcone D; Darzynkiewicz Z; Ciccone E; Fais F; Bruno S
Sci Rep; 2020 Oct; 10(1):16519. PubMed ID: 33020573
[TBL] [Abstract][Full Text] [Related]
2. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.
Song T; Chai G; Liu Y; Yu X; Wang Z; Zhang Z
Br J Pharmacol; 2016 Feb; 173(3):471-83. PubMed ID: 26493374
[TBL] [Abstract][Full Text] [Related]
3. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
[TBL] [Abstract][Full Text] [Related]
4. An acylhydroquinone derivative produces OXPHOS uncoupling and sensitization to BH3 mimetic ABT-199 (Venetoclax) in human promyelocytic leukemia cells.
Donoso-Bustamante V; Borrego EA; Schiaffino-Bustamante Y; Gutiérrez DA; Millas-Vargas JP; Fuentes-Retamal S; Correa P; Carrillo I; Aguilera RJ; Miranda D; Chávez-Báez I; Pulgar R; Urra FA; Varela-Ramírez A; Araya-Maturana R
Bioorg Chem; 2020 Jul; 100():103935. PubMed ID: 32454391
[TBL] [Abstract][Full Text] [Related]
5. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment.
Crassini K; Shen Y; Stevenson WS; Christopherson R; Ward C; Mulligan SP; Best OG
Br J Haematol; 2018 Aug; 182(3):360-372. PubMed ID: 29767411
[TBL] [Abstract][Full Text] [Related]
6. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
[TBL] [Abstract][Full Text] [Related]
7. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
8. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.
Anderson MA; Deng J; Seymour JF; Tam C; Kim SY; Fein J; Yu L; Brown JR; Westerman D; Si EG; Majewski IJ; Segal D; Heitner Enschede SL; Huang DC; Davids MS; Letai A; Roberts AW
Blood; 2016 Jun; 127(25):3215-24. PubMed ID: 27069256
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.
Guièze R; Liu VM; Rosebrock D; Jourdain AA; Hernández-Sánchez M; Martinez Zurita A; Sun J; Ten Hacken E; Baranowski K; Thompson PA; Heo JM; Cartun Z; Aygün O; Iorgulescu JB; Zhang W; Notarangelo G; Livitz D; Li S; Davids MS; Biran A; Fernandes SM; Brown JR; Lako A; Ciantra ZB; Lawlor MA; Keskin DB; Udeshi ND; Wierda WG; Livak KJ; Letai AG; Neuberg D; Harper JW; Carr SA; Piccioni F; Ott CJ; Leshchiner I; Johannessen CM; Doench J; Mootha VK; Getz G; Wu CJ
Cancer Cell; 2019 Oct; 36(4):369-384.e13. PubMed ID: 31543463
[TBL] [Abstract][Full Text] [Related]
10. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
Choudhary GS; Tat TT; Misra S; Hill BT; Smith MR; Almasan A; Mazumder S
Oncotarget; 2015 Jul; 6(19):16912-25. PubMed ID: 26219338
[TBL] [Abstract][Full Text] [Related]
11. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
12. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
[TBL] [Abstract][Full Text] [Related]
13. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
[TBL] [Abstract][Full Text] [Related]
14. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.
Khaw SL; Mérino D; Anderson MA; Glaser SP; Bouillet P; Roberts AW; Huang DC
Leukemia; 2014 Jun; 28(6):1207-15. PubMed ID: 24402163
[TBL] [Abstract][Full Text] [Related]
15. miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies.
Al-Harbi S; Choudhary GS; Ebron JS; Hill BT; Vivekanathan N; Ting AH; Radivoyevitch T; Smith MR; Shukla GC; Almasan A
Mol Cancer; 2015 Nov; 14():185. PubMed ID: 26537004
[TBL] [Abstract][Full Text] [Related]
16. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
Ten Hacken E; Valentin R; Regis FFD; Sun J; Yin S; Werner L; Deng J; Gruber M; Wong J; Zheng M; Gill AL; Seiler M; Smith P; Thomas M; Buonamici S; Ghia EM; Kim E; Rassenti LZ; Burger JA; Kipps TJ; Meyerson ML; Bachireddy P; Wang L; Reed R; Neuberg D; Carrasco RD; Brooks AN; Letai A; Davids MS; Wu CJ
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282833
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia.
Huelsemann MF; Patz M; Beckmann L; Brinkmann K; Otto T; Fandrey J; Becker HJ; Theurich S; von Bergwelt-Baildon M; Pallasch CP; Zahedi RP; Kashkar H; Reinhardt HC; Hallek M; Wendtner CM; Frenzel LP
Leukemia; 2015 Apr; 29(4):981-4. PubMed ID: 25376373
[No Abstract] [Full Text] [Related]
18. Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells.
Bruno S; Ledda B; Tenca C; Ravera S; Orengo AM; Mazzarello AN; Pesenti E; Casciaro S; Racchi O; Ghiotto F; Marini C; Sambuceti G; DeCensi A; Fais F
Oncotarget; 2015 Sep; 6(26):22624-40. PubMed ID: 26265439
[TBL] [Abstract][Full Text] [Related]
19. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia.
Yi X; Sarkar A; Kismali G; Aslan B; Ayres M; Iles LR; Keating MJ; Wierda WG; Long JP; Bertilaccio MTS; Gandhi V
Clin Cancer Res; 2020 Jul; 26(14):3856-3867. PubMed ID: 31937611
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
